is semaglutide bad for your kidneys Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future | Endocrine What are the risks of

Symptoms include severe headache, dizziness, rapid heartbeat, dark urine, dry mouth, and fatigue

If you tolerate the starting dose well, your provider may recommend staying at 0.25 mg through month one before increasing in month two

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomized 2,539 adults with obesity or overweight to tirzepatide 5 mg, 10 mg, or 15 mg weekly for 72 weeks

New drug delivery methods and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists demonstrate potent efficacy, with tirzepatide showing significant MACE reduction in its own CVOT

However, reaching optimal glycemic control typically requires 12-16 weeks, particularly as the dose is gradually titrated upward according to FDA-approved protocols

Yes, GLP-1/GIP medications are generally safe and well-tolerated